Showing 1601-1610 of 2042 results for "".
- Iveric Bio Forms Gene Therapy Inherited Retina Disease Scientific Advisory Committeehttps://modernod.com/news/iveric-bio-names-gene-therapy-inherited-retina-disease-scientific-advisory-committee/2479219/Iveric Bio has formed a “Gene Therapy Inherited Retina Disease Scientific Advisory Committee,” which will work closely with Iveric senior management to advance its gene therapy-inherited retinal disease pro
- Three Companies Combine to Form Corza Medicalhttps://modernod.com/news/three-companies-combine-to-form-corza-medical/2479217/Corza Medical, a provider of surgical products and technologies, was formed after uniting Surgical Specialties Corporation, Caliber Ophthalmics, and the TachoSil hemostatic patch device. &
- New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced AMD Progressionhttps://modernod.com/news/new-national-eye-institute-data-shows-areds2-nutrient-formula-continues-to-reduce-the-risk-of-moderate-to-advanced-amd-progression/2479193/Bausch + Lomb announced new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study. Based on this data, the NEI continues to recommend a specific nutrient formula to help
- ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat DED & Ocular Inflammationhttps://modernod.com/news/protokinetix-engages-multi-national-partner-for-formulation-of-topical-drug-to-treat-ded-ocular-inflammation/2479083/ProtoKinetix announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP. For the development of this drug for DED to date the company has completed:
- ForeseeHome AMD Home Monitoring Real-World Data Analysis Demonstrates Substantial Benefit for Patients’ Visionhttps://modernod.com/news/foreseehome-amd-home-monitoring-real-world-data-analysis-demonstrates-substantial-benefit-for-patients-vision/2479053/Real-world data on the performance of the ForeseeHome AMD Monitoring Program, a home-based diagnostic that helps detect the conversion from intermediate dry to wet age-related macular degeneration (AMD), was recently published in the Journal of Clinical Medicine as part of the “Diagnosis,
- Researchers Use Patients’ Cells to Test Gene Therapy for a Form of Leber Congenital Amauroshttps://modernod.com/news/researchers-use-patients-cells-to-test-gene-therapy-for-a-form-of-leber-congenital-amauros/2478810/Scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy for a rare disease that causes severe vision loss in childhood. A form of Leber congenital amaurosis, the disease is caused by autosomal-dominant mutations in the CRX gene, which are ch
- Aviceda Therapeutics Announces Formation of Executive Teamhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-executive-team/2478745/Aviceda Therapeutics has announced the composition of the Executive Team that will guide the company through ongoing development of first-in-class therapeutics and continued growth opportunities as a business entity. Aviceda’s lead ophthalmic optimized nanoparticle, as an intravitreal form
- Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies in Ophthalmic Diseaseshttps://modernod.com/news/maze-therapeutics-and-alloy-therapeutics-form-broadwing-bio-to-develop-antibody-therapies-in-ophthalmic-diseases/2478632/Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases. Broadwing Bio will advance programs directed to genetically validated ophthalmology targets identified using Maze’s human genetics and
- Outlook Therapeutics Provides Update on First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degenerationhttps://modernod.com/news/outlook-therapeutics-provides-update-on-first-approved-ophthalmic-formulation-of-bevacizumab-vikg-for-advanced-macular-degeneration/2478349/Outlook Therapeutics announced progress on its phase 3 clinical program for the first FDA-approved ophthalmic formulation of bevacizumab-vikg (Lytenava) for use in retinal indications (known as ONS-5010 for use in retinal indications). Outlook plans the commercial launch of ONS-5010 in 202
- ForwardVue Pharma Secures Funding to Advance Preclinical Development Programshttps://modernod.com/news/forwardvue-pharma-secures-funding-to-advance-preclinical-development-programs/2478206/ForwardVue Pharma has secured initial seed round funding in order to advance preclinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration. Based on this progress, ForwardVue has announced a ne